First Participant Dosed in Phase 1/2 Study of Modern’s Quadrivalent Seasonal Flu mRNA Vaccine

The examine plans to enroll roughly 180 contributors to guage the protection, reactogenicity, and immunogenicity of its quadrivalent seasonal influenza mRNA vaccine in adults 18 years and older.

Investigators have dosed the primary participant in a section 1/2 examine of mRNA-1010, Moderna’s quadrivalent seasonal influenza mRNA vaccine candidate, in response to a press launch.

It’s the firm’s first seasonal influenza vaccine candidate to enter the clinic. mRNA-1010 targets lineages really helpful by the World Well being Group for the prevention of influenza, together with seasonal influenza A H1N1, H3N2, and influenza B Yamagata and Victoria.

The randomized, stratified, observer-blind, dose-ranging examine will consider the protection, reactogenicity, and immunogenicity of the vaccine candidate in adults 18 years of age and older. Investigators plan to enroll roughly 180 contributors.

“We count on that our seasonal influenza vaccine candidates will probably be an necessary part of our future mixture respiratory vaccines,” stated Stephane Bancel, CEO of Moderna, within the press launch. “Respiratory mixture vaccines are an necessary pillar of our total mRNA vaccine technique. We consider that some great benefits of mRNA vaccines embody the power to mix completely different antigens to guard in opposition to a number of viruses and the power to quickly reply to the evolution of respiratory viruses, corresponding to influenza.”

Present flu vaccines are solely roughly 40% to 60% efficient, with formulations determined 6 to 9 months earlier than the vaccines are meant for use. Roughly 8% of the USA inhabitants experiences flu signs every year, with an estimated common financial burden of roughly $11 billion per 12 months as a consequence of influenza, in response to the press launch.

Egg-based vaccine manufacturing is used for almost all of presently licensed influenza vaccines, though it has elevated potential for unintended antigenic change to the vaccine virus. Moderna plans to discover potential mixture vaccines for the flu, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus, in response to the press launch. The corporate’s overarching seasonal flu program intends to guage a number of vaccine candidates with completely different antigen combos.

“Our imaginative and prescient is to develop an mRNA mixture vaccine so that individuals can get one shot every fall for prime efficacy safety in opposition to probably the most problematic respiratory viruses,” Bancel stated within the press launch.


Moderna Declares First Participant Dosed in Section 1/2 Research of Its Quadrivalent Seasonal Flu mRNA Vaccine. Information launch. Moderna. July 7, 2021. Accessed July 9, 2021.


Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button